Evommune EVMN 深 滬
等待開盤 09-25 09:30:00 美东时间
8.80
+0.030
+0.34%
華盛通- 最 高8.90
- 今 開8.73
- 成交量 99.22万股
- 最 低 8.25
- 昨 收 8.77
- 總市值 3.19亿
- 52周最高 33.20
- 市盈率 靜 --
- 換手率 2.73%
- 52周最低 8.25
- 委 比 33.33%
- 總股本 3629.21万
- 歷史最高 33.20
- 量 比 1.26
- 振 幅 7.41%
- 歷史最低 8.25
- 每 手 1
- 風險率 5.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be ...
09-24 04:06
What's Going on With Cue Biopharma Stock on Monday?
Cue Biopharma (NASDAQ:CUE) on Sunday shared topline results from a Phase 2 trial of CUE-221 in patients with moderate to severe chronic spontaneous urticaria. The study met its primary and secondary endpoints, demonstrating sustained efficacy and a favorable safety profile. Cue Biopharma shares init...
09-21 22:45
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.
09-09 21:33
Evommune Halts Atopic Dermatitis Program Following Trial Failure
On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. Phase 2b Clinical Trial Findings The study evaluated the efficacy and safety profile of oral EVO75...
09-09 19:40
HC Wainwright & Co. Reiterates Neutral on Evommuneto Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) from Neutral to Neutral.
09-09 18:32
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.
08-26 18:47
